A Personalized Prevention Program (PPP) Based on the Comprehensive Geriatric Assessment (CGA) for the Prevention of Multidimensional Frailty Related to Non-communicable Chronic Diseases (NCDs) in Older People

NCT06224556 — Not applicable, Unknown, 1216 participants, Alberto Pilotto

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Personalized Prevention Program (PPP) Based on the Comprehensive Geriatric Assessment (CGA) for the Prevention of Multidimensional Frailty Related to Non-communicable Chronic Diseases (NCDs) in Older People: a Practical Approach in Primary Care Setting

RegistryNCT06224556, acronym PrimaCare_P3
StatusUnknown
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: single, prevention
Enrollment1216 (Estimated)
SponsorAlberto Pilotto (Other)
ConditionsOlder People, Non-Communicable Chronic Diseases
InterventionsBrief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program (Combination product)
Datesstart 2024-06-04, primary completion 2025-05-01 (estimated), completion 2025-05-01 (estimated), first posted 2024-01-25, last updated 2024-08-28
Locations4 sites in Italy

Related Papers Related Patents Related Grants Related Experts
All trials for Older People All trials for Non-Communicable Chronic Diseases All trials of Brief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program

-Summary

* Non-Communicable Diseases (NCDs) can accelerated the aging process and increase the frailty condition
* The Comprehensive Geriatric Assessment (CGA) is the gold standard in the geriatric clinical context
* Recently, in Italy the first Guidelines about the CGA in different settings for older people has been pubblicated
* The CGA can identify older people at high risk of frailty who can benefit from a personalized prevention program
* No studies has been investigated the effects of a personalized prevention program (PPP) based on the CGA in a primary care setting
* The main hypothesis is that the CGA assessment can result in personalized prevention programs for older subjects in primary care settings with an effect in reducing the hospitalization rate and can be related to the biological paramters in NCDs

Expand all sections  ·  Collapse all

+Detailed description

The main aim of the project is to evaluate in older people the effectiveness of personalized preventive interventions based on the Comprehensive Geriatric Assessment (CGA) in the primary care setting and to explore biological process in Non-Communicable Disases (NCDs).

The study involves 1216 subjects enrolled by General Practitioners (GPs) in four different Italian Areas.

The GPs involved will be randomised to clusters in a 1:1 ratio, therefore one group of GPs will enrol patients for the Intervention Group and a second group of GPs will include patients for the Control Group.

The sample size:

A recent Cochrane systematic review reports a significant reduction in the risk of unplanned hospitalisation in community-dwelling elderly persons treated with VMD compared to standard clinical practice (RR= 0.83; CI 95%: 0.70-0.99). Thus, assuming an incidence of unplanned hospitalisations in one year of 38.8% in the group receiving PPP compared to 47.7% in the group randomised to standard care and assuming a power of 80% and a type I error of 5%, a total of 972 participants will be enrolled. Furthermore, assuming a drop-out rate of 20% over the 1-year follow-up period, the final sample will be 1216 participants, 608 in each group

608 subjects will be involved in the intervention group: they will receive the Personalized Prevention Program (PPP) and a saliva sample will be collected.

608 subjects will be involved in the control group according to the normal clinical practice.

Both groups will be contacted at 6 and 12 months after the baseline for the follow-up.

Statistical analyses:

Baseline characteristics will be compared between the group receiving the CGA-based PPP intervention and the control group. Continuous variables will be compared using the t-Student test and categorical variables using the Chi-square test. The cumulative probability of the primary and secondary outcome will be estimated by Kaplan-Meier curve, using the log-rank test to assess differences between the two groups. To assess the risk associated with the primary outcome (rate of unplanned hospitalisation at 12 months) in subjects in the intervention group compared to subjects in standard care, the Hazard Ratio (HR) will be estimated by fitting a Cox model, after testing for proportional hazards. Similarly, the risk of secondary outcomes will be estimated.

+Arms and interventions

ArmTypeInterventionsDescription
Intervention GroupExperimentalCombination Product: Brief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention ProgramAll the 608 patients will be evaluated by their General Practitioners through the Brief-MPI scale, which is based on the Comprehensive Geriatric Assessment (CGA). Based on the score obtained at the Brief-MPI, the patient will receive a Personalised Prevention Program (PPP) concerning the following domains: 1) motor, 2) cognitive, 3) nutritional, 4) polypharmacotherapy, 5) vaccination prevention, 6) basal and instrumental activities, 7) co-habitation. Patients will receive brochures containing practical advice and recommendations to be implemented over a 12-month period; in the case of high Brief-MPI risk scores, patients will be referred for specialist examinations and/or in-depth diagnostics. In addition, saliva samples will be collected to assess biomarkers of oxidative stress and, in a subsample of 210 subjects, the composition of the oral microbiota will also be analysed.
Control groupNo interventionPatients will receive the standard clinical practice by their General Practitioners, without being evaluated by the CGA or receiving the personalized prevention program (PPP). No saliva sample will be collected.
  • Brief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program (Combination product): Patients will be evaluated at baseline and at 6 and 12 months after the baseline through the CGA, the Resilience Scale (RS-14 items) and the Psychological General Wellbeing Index short form. The prevention program will be received at the baseline, so at the two follow-ups patients wiil asked the adherence to it and the level of satisfaction (Client Satisfaction Questionnaire - 8 items). Saliva sample will be collected and analyzed.

+Outcome measures

Primary outcomes

  • Hospitalization rate [12 months]: Unplanned hospitalization rate

Secondary outcomes

  • Composed outcome [6 and 12 months]: Composed outcome including: emergency access rate, hospitalization and institutionalization rates at 6 and 12 months after the baseline.
  • Number of unplanned General Practitioners visits [12 months]: Unplanned GPs visits
  • Mortality rate [6 and 12 months]: mortality rate at 6 and 12 months

Other outcomes

  • Adherence at the PPP [6 and 12 months]: Adherence at the Personalized Prevention Program by the Intervention Group
  • Psychological Well-being [Baseline, 6 and 12 months]: Psychological well-being assessed to the Intervention Group
  • Resilience [Baseline, 6 and 12 months]: Resilience outcome evaluated in the Intervention Group
  • Lactate in the Intervention Group [After the saliva collection at the baseline]: Saliva analyses for the Lactate parameter
  • NAD/NADH in the Intervention Group [After the saliva collection at the baseline]: Saliva analyses for theNAD/NADH parameter
  • TBARS in the Intervention Group [After the saliva collection at the baseline]: Saliva analyses for the TBARS parameter
  • TNF-alfa in the Intervention Group [After the saliva collection at the baseline]: Saliva analyses for theTNF-alfa parameter
  • IL-1b in the Intervention Group [After the saliva collection at the baseline]: Saliva analyses for the IL-1b parameter
  • IL-6 in the Intervention Group [After the saliva collection at the baseline]: Saliva analyses for the IL-6 parameter
  • IL-8 in the Intervention Group [After the saliva collection at the baseline]: Saliva analyses for the IL-8 parameter
  • Microbioma saliva analysis in a sub-group of the Intervention Group [After the saliva collection at the baseline]: The microbioma saliva sample will be analysed in 210 subjects from the Intervention Group through the DNA GENOTEK OME-505 Omnigene Oral Collection Kits for Nucleic Acid Saliva

+Eligibility

Sex: All, ages: 65 Years to any

Inclusion Criteria:

* 65 years old and over
* At least 1 non-communicable chronic disease
* Signed informed consent

Exclusion Criteria:

* not willing in partecipating in the study and no signed informed consent
* <65 years old
* without non-communicable chronic diseases

+Locations (4)

FacilityCityCountryStatus
Polimedica Societa' CooperativaBariItalyRecruiting
Medici Insieme Garda Valsabbia Societa' CooperativaDesenzano del GardaItalyRecruiting
Ambulatori mediciFlorenceItalyRecruiting
COMEGEN Società Cooperativa SocialeNaplesItalyRecruiting

+Publications

  • Results publication: Pilotto A, Morganti W, Seminerio E, Lacorte E, Custodero C, Veronese N, Fielding P, Massone C, Piscopo P, Fabrizi E, Lorenzini P, Magni A, Piccinocchi G, Ignazzi C, Busco L, Barbagallo M, Massone C, Aprile PL, Vanacore N. Usefulness of the BRIEF-Multidimensional Prognostic Index (BRIEF-MPI) to identify older adults' healthcare needs to be addressed with a Personalized Prevention Program in general practice: preliminary data from the PrimaCare_P3 study. BMC Prim Care. 2025 Oct 27;26(1):323. doi: 10.1186/s12875-025-02951-6. PMID 41146026
  • Results publication: Pilotto A, Barbagelata M, Lacorte E, Custodero C, Veronese N, Maione V, Morganti W, Seminerio E, Piscopo P, Fabrizi E, Lorenzini P, Carbone E, Lora Aprile P, Solfrizzi V, Barbagallo M, Vanacore N; PrimaCare_P3 study group. A multicomponent personalized prevention program in the primary care setting: a randomized clinical trial in older people with noncommunicable chronic diseases (Primacare_P3 study). Trials. 2024 Sep 13;25(1):611. doi: 10.1186/s13063-024-08413-1. PMID 39272196

+Investigators

  • Alberto Pilotto, Principal investigator, Director of the Department of Geriatric Care, orthogeroatric and rehabilitation, EO Galliera Hospital, Genova, Italy